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The authors present a case of an 80-year-old Caucasian male with multiple gastric and rectal metastases frommalignant melanoma
presenting with hypochromic anemia as the sole symptom of disease without evidence of cutaneous and ocular tumor localization.
The patient had a medical history positive for malignant lentigo melanoma of the occipital region of the scalp and early stage
laryngeal squamous cell carcinoma and prostatic carcinoma treated with radiation therapy.The authors make some considerations
on intestinal involvement by metastatic melanoma and discuss the choice of not treating with endoscopic procedures the gastric
metastatic lesions most likely responsible for the clinical sign present at diagnosis. The patient was referred to clinical oncologists
and received immunotherapy with ipilimumab and pembrolizumab.
1. Introduction
Metastatic involvement of the gastrointestinal tract by epithe-
lial malignancies is a rather infrequent event as opposed to
malignant melanoma, which appears to have a particular
trend towards metastasis to the gut [1]. In fact, autopsy
series report up to 60% pathological intestinal involvement
in patients that deceased once diagnosed with metastatic
melanoma, which however reaches clinical relevance in a
median of 2% of patients only (range: 0.8–8.9%) [2, 3].
The wide range of incidences can be partly explained by
difficulties in exploring the small intestine, which usually
represents the most frequent localization of gastrointestinal
metastasis, as well as the absence of specific symptoms
which are more frequently reported in gastric and duodenal
localization more easily accessible for diagnostic study [4].
2. Objective
The objective of this paper is to present a case of an
unusual clinical presentation of metastatic melanoma with
hypochromic anemia refractory to iron therapy treated
with endoscopic procedures and systemic immunotherapy.
Review of the literature is also reported below.
3. Case Report
In 2004, an 80-year-old Caucasian male underwent bilateral
cordectomy for Tis carcinoma in the left cord and microin-
vasive T1 carcinoma at the right one. In the same year, he
was diagnosed with prostatic carcinoma (Gleason score 3 +
3) which was treated with radiation therapy for a final total
dose of 64Gy. Since then, he has been controlled regularly on
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a 6-month basis. His family history was negative for cancer,
but he suffered frommild hypertension that has been treated
with a sartan drug for 17 years, and he also suffered frommild
dyslipidemia without anymedication besides dietary control.
In January 2014, he was admitted at the dermatologic
unit of our institution for a pigmented cutaneous lesion at
the occipital region of the scalp and an ulcerated lesion in
the left temporal region, which were both radically excised.
The pathologist reported a BRAF, c-KIT, and N-RAS wild-
type lentigo maligna melanoma in the occipital scalp, while
the ulcerated lesion at the temporal region was classified as
an actinic keratosis. Full skin and ocular examinations, chest
X-rays, and abdominal sonogram excluded the presence of
clinical detectable neoplastic deposits. Due to his medical
history, the patient was admitted to a three-month follow-up
program. In January 2015, for the appearance of a swelling in
the left parotid gland, he received an MRI and a subsequent
biopsy, which led to a diagnosis of pleomorphic adenoma.
In May 2014, he was diagnosed with hypochromic, iron-
deficiency anemia in the absence of overt clinical signs of
bleeding and normal urine analysis. Fecal occult blood test
was strongly positive.Thepatient was put on oral iron therapy
without positive results for three months and therefore was
referred to the endoscopy unit for upper and distal gastroin-
testinal tracts examination. Esophagogastroduodenoscopy
showed the presence of several nonbleeding, bluish to black,
gastric lesions of a few millimeters in diameter (Figures 1
and 2). Such lesions were present in the whole stomach
with an increased frequency in the corpus and the antrum
but were absent in the esophageal tract and the duodenal
level until Treitz’s ligament. Biopsy of the three lesions was
performedwithout significant bleeding.Morphologically, the
lesions appeared suggestive for metastatic melanoma. Pan-
colonoscopy was performed two days later and showed no
widespread injuries except for two 5mm wide, brownish,
nonbleeding areas 2 cm away from each other at the rectal
mucosa about 15 cm from the anal verge. Biopsywas suddenly
performed although the morphological features of these
rectal lesions were consistent with mucosal angiodysplastic
lesions similar to those often found after radiation therapy for
prostate tumors. Pathology examination of both gastric and
rectal specimens reported the presence of HMB45, MelanA-
S100+, Cd68 negative, infiltrating malignant melanoma.
PET/TC scan showed a metastatic lesion in the lumbar
spine and the left clavicle, with the latter being biopsied.
Pathology reported metastatic melanoma to the bone. PSA
and serum chemistry tests were within the normal limits.
Careful skin mapping as well ocular examination failed
to show presence of cutaneous melanoma. In April 2015,
rectal lesions were endoscopically treated with argon plasma
coagulation, while gastric lesions were left untreated. The
patient was subsequently referred to the Medical Oncol-
ogy Unit and, after we obtained written informed consent,
we started immunotherapy with ipilimumab 3mg/kg every
three weeks. After 3 months, he showed rapidly progressing
disease with the appearance of melena and worsening of
anemia. Therefore, ipilimumab was stopped and in July 2015
pembrolizumab was started at the dose of 2mg/kg every
three weeks. Reevaluation of the disease after three months
Figure 1: Presence of several medium size melanotic lesions in the
fundus and the body of the stomach.
Figure 2: Melanotic lesions are less frequent in the distal part of the
stomach.
showed a PET/TC-documented stabilization of the disease
and a significant improvement of clinical conditions and
hemoglobin levels with a dramatic reduction of transfusion
needs. Pembrolizumab was very well tolerated with mild
gastrointestinal and cutaneous toxicity, easily managed with
low dose steroids. Pembrolizumabwas given for eightmonths
till March 2016 when progressive disease to the liver and the
brain was recorded. Unfortunately, the patient died 4 months
later due to massive liver progression.
4. Considerations
Primary malignant gastrointestinal melanoma may arise in
several areas of the digestive tract: 33% of the cases are located
in the nasopharynx, 5.9% in the esophagus, 2.7% in the
stomach, 2.3% in the small intestine, 1.4% in the gallbladder,
9% in the colon, 22% in the rectum, and 31% in the anal
tract [1–6]. On the other hand, primary cutaneousmelanoma
with gastrointestinal metastasis may be localized in the head
and neck region (3–33%), being much more frequent in the
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limbs (15–57%) and the trunk (13–54%) [1–6]. Overall, 20%of
caseswith gastrointestinalmetastasis frommelanomapresent
gastric metastases, 58% small intestine lesions, and 22%
colorectal lesions. Cutaneousmelanomahas a distinct pattern
of metastasis, preferentially targeting the submucosa of the
small intestine probably via the CCR9 lymphocytes, CCL25
thymus-expressed chemokine axis, and specific integrins [7].
The incidence of intestinal metastasis is also related to Clark
level of the primary lesion, being less than 6% for level I, 6 to
24% for level II, and more than 70% for level III or greater.
Endoscopically, gastric metastasis from melanoma may
appear as black-pigmented ulcers, diffuse black pigment in
the context of mucosa, multiple small size nodules of the
mucosa or submucosa, polypoid lesions, or extrinsic masses
[8]. These lesions are often pigmented but may be non-
pigmented, mimicking other forms of neoplastic epithelial
lesions or MALT lymphomas [1–6]. However, the major-
ity of patients with gastrointestinal metastatic spread from
malignant melanoma present multiple metastases localized
to the small intestine with a wide morphological variability
[9]. Symptoms are often modest and rather nonspecific, and
clinical indication for endoscopic study stems only from the
need to find the cause of occult bleeding responsible for
chronic, iron-deficiency anemia as in this patient [4]. Unfor-
tunately, intestinal metastases from melanoma may lead to
nonspecific surgical and medical emergency conditions such
as bowel obstruction and/or perforation, dyspepsia, nausea
and vomiting, abdominal pain, weight loss, diarrhea, and
overt bleeding [10]. More rarely, metastatic deposits may
cause, as in the present case, chronic hypochromic anemia.
Clinically silent gastrointestinal metastases can be present
in an increasing percentage of cases, therefore rendering
it reasonable to include endoscopy in follow-up exams of
selected patients with mild gastroenteric symptoms [4].
Biopsy during the endoscopic procedure is mandatory since
many polypoid lesions can be nonmelanotic. For this reason,
in patients with a history of melanoma in which endoscopic
polypoid lesion is observed, the presence of a nonpigmented
lesion is a plausible suspicion of a possible metastatic lesion.
The soft capsule study of the ileum, despite its limitations,
could provide further data due to the higher frequency of
metastasis localization in this intestinal tract [11]. PET/CThas
a very high sensitivity in detectingmetastasis frommelanoma
[12, 13]. In our case, the PET-CT showed vertebral and
clavicular metastases, which however were biopsied to rule
out metastatic deposits from other neoplasms since medical
history was positive for prostate and larynx cancer. However,
PET/TC was not able to show metastatic lesions or gastric
lesions. In such cases, the role of surgery is palliative [14]. Sur-
gical interventions for symptomatic patients with melanoma
of the gastrointestinal tract significantly relieve pain and
improve quality of life and may confer a survival advantage.
Medical oncologists choose systemic immunotherapy
with the monoclonal anti-CTLA4 antibody ipilimumab,
which has been proven to be effective in the treatment of
metastatic melanoma. In fact, ipilimumab, with or without
a gp100 peptide vaccine, as compared with gp100 alone,
improved overall survival in patients with previously treated
metastatic melanoma [15]. The median overall survival was
10.0months among patients receiving ipilimumab plus gp100,
as comparedwith 6.4months among patients receiving gp100
alone (hazard ratio for death: 0.68; 𝑃 < 0.001). The median
overall survival with ipilimumab alone was 10.1 months (haz-
ard ratio for death in comparison with gp100 alone: 0.66; 𝑃 =
0.003). No difference in overall survival was detected between
the ipilimumab groups (hazard ratio with ipilimumab plus
gp100: 1.04; 𝑃 = 0.76). At progression after ipilimumab treat-
ment, the patientwas offered to start second-line therapywith
the anti-PD-1 monoclonal antibody pembrolizumab accord-
ing to the results of the Keynote-002 trial [16]. This phase
II study compared two different doses (2 versus 10mg/kg
every three weeks) of pembrolizumab versus investigator-
choice chemotherapy (paclitaxel plus carboplatin, paclitaxel,
carboplatin, dacarbazine, or oral temozolomide) in a series
of patients with metastatic melanoma pretreated with ipil-
imumab. Both dosages of pembrolizumab were superior
to chemotherapy in terms of progression-free survival (5.5
months versus 5.8 versus 3.6 months, resp.). A subsequent
phase III clinical trial showed that pembrolizumab was more
active than ipilimumab in terms of PFS. The estimated 6-
month progression-free survival rates were 47.3% for patients
receiving pembrolizumab every 2 weeks, 46.4% for those
receiving pembrolizumab every 3 weeks, and 26.5% for those
receiving ipilimumab. Median estimates of progression-free
survival were 5.5months, 4.1months, and 2.8months, respec-
tively. A recent review comprising all open-label studies with
pembrolizumab reported a 33% overall response rate with a
rate of 35% a year equal to the PFS and finally an overall
median survival of 23 months [17]. Only 14% of patients
treated with pembrolizumab developed grade 3 toxicity. The
patient experienced an eight-month progression-free sur-
vival, longer than median PFS reported for pembrolizumab,
with an excellent tolerability that enabled him to maintain a
good quality of life with optimal symptom control.
5. Conclusions
This case is intriguing for both clinical presentation and
treatment challenges. In fact, occult gastrointestinal bleeding
as the first clinical presentation ofmetastaticmelanoma is rel-
atively unusual, especially in the absence of other symptoms
of disease. Gastrointestinal metastasis, especially of the small
intestine, always represents an advanced stage of the disease
even in the absence of other evidence of disease and should be
always suspected in patients with gastrointestinal symptoms
and history of cutaneous melanoma. The massive involve-
ment of the stomach and the coexistence of rectal lesions
as well as the simultaneous presence of bone metastasis are
suggestive for metastatic spread rather than a primitive gas-
trointestinalmelanoma.Therefore, after intensiveworkup, we
concluded that gastrointestinal metastatic lesions detected in
this casemay be secondary to the excisedmalignant lentigo at
the occipital region of the scalp even if this neoplastic malig-
nant disease is reported to have a low metastatic potential.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
4 Case Reports in Oncological Medicine
References
[1] K. Patel, S. T. Ward, T. Packer et al., “Malignant melanoma of
the gastro-intestinal tract: A case series,” International Journal
of Surgery, vol. 12, no. 5, pp. 523–527, 2014.
[2] I. Oda, H. Kondo, T. Yamao et al., “Metastatic tumors to the
stomach: analysis of 54 patients diagnosed at endoscopy and 347
autopsy cases,” Endoscopy, vol. 33, no. 6, pp. 507–510, 2001.
[3] J. K. Patel, M. S. Didolkar, J. W. Pickren, and R. H. Moore,
“Metastatic pattern of malignant melanoma: a study of 216
autopsy cases,”The American Journal of Surgery, vol. 135, no. 6,
pp. 807–810, 1978.
[4] J. G. Albert, M. Fechner, E. Fiedler et al., “Algorithm for detec-
tion of small-bowel metastasis in malignant melanoma of the
skin,” Endoscopy, vol. 43, no. 6, pp. 490–498, 2011.
[5] L. M. Schuchter, R. Green, and D. Fraker, “Primary and meta-
static diseases in malignant melanoma of the gastrointestinal
tract,” Current Opinion in Oncology, vol. 12, no. 2, pp. 181–185,
2000.
[6] S. Kruger, F.Noack, C. Blochle, andA.C. Feller, “Primarymalig-
nant melanoma of the small bowel: a case report and review of
the literature,” Tumori, vol. 91, no. 1, pp. 73–76, 2005.
[7] F. F. Amersi, A. M. Terando, Y. Goto et al., “Activation of CCR9/
CCL25 in cutaneous melanoma mediates preferential metasta-
sis to the small intestine,” Clinical Cancer Research, vol. 14, no.
3, pp. 638–645, 2008.
[8] D. A. Benedeto-Stojanov, A. V. Nagorni, V. V. Zˇivkovic´, J. R.
Milanovic´, and D. A. Stojanov, “Metastatic melanoma of the
stomach and the duodenum,” Archive of Oncology, vol. 14, no.
1-2, pp. 60-61, 2006.
[9] G. N. Bender, D. D. T. Maglinte, J. H. McLarney, D. Rex, and
F. M. Kelvin, “Malignant melanoma: Patterns of metastasis
to the small bowel, reliability of imaging studies, and clinical
relevance,” American Journal of Gastroenterology, vol. 96, no. 8,
pp. 2392–2400, 2001.
[10] F. A. Alvarez,M. Nicola´s, J. Goransky, C. A. Vaccaro, A. Beskow,
and D. Cavadas, “Ileocolic intussusception due to intestinal
metastatic melanoma. Case report and review of the literature,”
International Journal of Surgery Case Reports, vol. 2, no. 6, pp.
118–121, 2011.
[11] H. Issa, A. M. Poovathumkadavil, F. Almousa, and A. H. Al-
Salem, “Metastatic malignant melanoma of the small intestines
diagnosed by capsule endoscopy,” Gastroenterology Research,
vol. 4, no. 5, pp. 236–239, 2012.
[12] S. M. Swetter, L. A. Carroll, D. L. Johnson, and G. M. Segall,
“Positron emission tomography is superior to computed tomog-
raphy for metastatic detection in melanoma patients,”Annals of
Surgical Oncology, vol. 9, no. 7, pp. 646–653, 2002.
[13] E. Bastiaannet, C. A.Uyl-DeGroot, A.H. Brouwers et al., “Cost-
effectiveness of adding FDG-PET or CT to the diagnostic work-
up of patients with stage III melanoma,” Annals of Surgery, vol.
255, no. 4, pp. 771–776, 2012.
[14] S. Shenoy and R. Cassim, “Metastatic melanoma to the gas-
trointestinal tract: role of surgery as palliative treatment,”West
Virginia Medical Journal , vol. 109, no. 1, pp. 30–33, 2013.
[15] F. S. Hodi, S. J. O’Day, andD. F.McDermott, “Improved survival
with ipilimumab in patients with metastatic melanoma,” The
New England Journal of Medicine, vol. 363, no. 8, pp. 711–723,
2010.
[16] A. Ribas, I. Puzanov, R. Dumme et al., “Pembrolizumab versus
investigator-choice chemotherapy for ipilimumab-refractory
melanoma (KEYNOTE-002): a randomised, controlled, phase
2 trial,” Lancet Oncology, vol. 16, no. 8, pp. 908–918, 2015.
[17] O. Abdel-Rahman, D. Helbling, J. Schmidt et al., “Treatment-
related Death in Cancer Patients Treated with Immune Check-
point Inhibitors: A Systematic Review and Meta-analysis,”
Clinical Oncology, vol. 29, no. 4, pp. 218–230, 2017.
